Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLX10010 for hypertrophic scar recurrence
NCT04877756Phase 2Completed
- Sponsor
- OliX Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Jan 2023
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of OLX10010 in Hypertrophic Scar (HS), sponsored by OliX Pharmaceuticals. Started Aug 2021; status: completed.
02
Drugs
OLX10010
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT04877756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877756.